The Summary
In a 52-week clinical trial of 1,698 adults with type 2 diabetes, researchers compared the new oral drug orforglipron (12 mg and 36 mg) with oral semaglutide (7 mg and 14 mg). Both doses of once-daily orforglipron proved superior at lowering HbA1c levels compared to semaglutide. For instance, the 36 mg dose of orforglipron reduced HbA1c by 1.91%, compared to 1.47% for 14 mg of semaglutide. However, orforglipron caused more gastrointestinal side effects, higher treatment discontinuation rates, and a slightly larger increase in heart rate than semaglutide.
Why this is interesting
Unlike oral semaglutide, which requires strict fasting and water restrictions to work, orforglipron is a non-peptide pill that can be taken anytime without food or water constraints. It was previously thought that oral peptide GLP-1s were the peak of convenience, but this new compound offers even greater flexibility and superior blood sugar control. For readers, this marks a major step toward highly effective, hassle-free daily pills for diabetes management, though the higher risk of stomach side effects means patients will need to weigh benefits against tolerability.